Resultados de Búsqueda por Autor

artículo

Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

Publicado por
Echavarria, I, López-Tarruella, S, Picornell, A, García-Saenz, JÁ, Jerez, Y, Hoadley, K, Gomez, HL, Moreno, F, Monte-Millan, MD, Márquez-Rodas, I, Alvarez, E, Ramos-Medina, R, Gayarre, J, Massarrah, T, Ocaña, I, Cebollero, M, Fuentes, H, Barnadas, A, Ballesteros, AI, Bohn, U, Perou, CM, Martin, M

Publicado 2018

Enlace

Purpose: Triple-negative breast cancer (TNBC) requires the iden- tification of reliable predictors of response to neoadjuvant chemotherapy (NACT). For this purpose, we aimed to evaluate the performance of the TNBCtype-4 classifier in a cohort of patients with TNBC treated with neoadjuvant carboplatin and docetaxel (TCb).Methods: Patients with TNBC were accrued in a nonrandomized trial of neoadjuvant carboplatin AUC 6 and docetaxel 75 mg/m2 for six cycles. Response was evaluated in terms of pathologic complete response (pCR, ypT0/is ypN0) and residual cancer burden by Symmans and colleagues. Lehmann's subtyping was performed using the TNBCtype online tool from RNAseq data, and germline sequencing of a panel of seven DNA damage repair genes was conducted.Results: Ninety-four out of the 121 patients enrolled in the trial had RNAseq available. The overall pCR rate was 44.7%. Lehmann subtype ...

artículo

Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

Publicado por
Sharma, P, López-Tarruella, S, García-Saenz, JA, Khan, QJ, Gómez, HL, Prat, A, Moreno, F, Jerez-Gilarranz, Y, Barnadas, A, Picornell, AC, Monte-Millán MD, González-Rivera, M, Massarrah, T, Pelaez-Lorenzo, B, Palomero, MI, González Del Val, R, Cortés, J, Fuentes-Rivera H, Morales, DB, Márquez-Rodas, I, Perou, CM, Lehn, C, Wang, YY, Klemp, JR, Mammen, JV, Wagner, JL, Amin, AL, O'Dea, AP, Heldstab, J, Jensen, RA, Kimler, BF, Godwin, AK, Martín, M

Publicado 2018

Enlace

Purpose: Prognostic value of pathologic complete response (pCR) and extent of pathologic response attained with anthracycline-free platinum plus taxane neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) is unknown. We report recurrence-free survival (RFS) and overall survival (OS) according to degree of pathologic response in patients treated with carboplatin plus docetaxel NAC. Patients and methods: One-hundred and ninety patients with stage I-III TNBC were treated with neoadjuvant carboplatin (AUC6) plus docetaxel (75 mg/m2) every 21 days × 6 cycles. pCR (no evidence of invasive tumor in breast and axilla) and Residual cancer burden (RCB) were evaluated. Patients were followed for recurrence and survival. Extent of pathologic response was associated with RFS and OS using the Kaplan-Meier method. Results: Median age was 51 years, and 52% were node-positive. pCR and ...